search
Back to results

Comparison of Efficacy and Side Effects Between the Obtryx and Solyx Band With 5-year Follow-up.

Primary Purpose

Stress Urinary Incontinence

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Solyx™ SIS System
Obtryx™ II System (Halo)
Sponsored by
Instituto de Investigacion Sanitaria La Fe
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stress Urinary Incontinence focused on measuring Stress Urinary Incontinence

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • patients diagnosed with symptomatic stress urinary incontinence candidates for stress-free bands
  • Age > or = 40 years
  • informed consent signed by the patient

Exclusion Criteria:

  • patients who are pregnant or wish to become
  • patients who need anticoagulant
  • active vaginal or urinary infection
  • previous surgical interventions for the treatment of incontinence
  • body mass index > 35

Sites / Locations

  • Hospital Universitario y Politécnico La FeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

S (SOLYX)

O (OBTRYX II)

Arm Description

The Solyx™SIS System is an innovative mid-urethral sling single incision system consisting of a 9 cm long polypropylene mesh, whose mid-urethral portion (4 cm) is detanged to potentially resist deformation and to reduce irritation to the urethral wall. Snap-fit to delivery device tip allows for advanced placement control and, therefore, the tensioning through the forward and reverse functions performed with this delivery device.

The Obtryx II System (Halo) is a transobturator sling designed to allow inter-operative adjustability with minimal tissue disruption. It consists of two delivery devices (one patient right and one patient left) and one mesh assembly. The mesh assembly is comprised of a polypropylene knitted mesh with dilator legs and a center tab. At the distal ends of the dilator legs there are association loops designed to be placed in the needle slot of the distal end of the delivery device. The disposable delivery device consists of a handle with a stainless steel needle. The needle is designed to facilitate the passage of the mesh assembly through bodily tissues for placement through the obturator foramen.

Outcomes

Primary Outcome Measures

Continence rate (Objective) assessed by an effort test
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Continence rate (Objective) assessed by an effort test
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Continence rate (Objective) assessed by an effort test
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Continence rate (Objective) assessed by an effort test
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Continence rate (Objective) assessed by an effort test
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Continence rate (Objective) assessed by an effort test
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Continence rate (Objective) assessed by an effort test
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.

Secondary Outcome Measures

Continence rate (Subjective) assessed by Incontinence Questionnaire-Urinary Short Form (ICQ-SF)
Incontinence Questionnaire-Urinary Short Form (ICQ-SF): continent patient when the reduction is equal to or greater than 50% of the value prior to the intervention.
Pad test
1 hour pad test: After a spontaneous urination the patient will place a compress that will be weighed previously. After, the patient has to drink a half liter of water in 15 minutes sitting. Between the minute 15 to 45 has to walk and / or go up / down stairs. From minute 45-60 the patient has to get up and sit 10 times, cough 10 times, run 1 minute, lift an object from the ground 10 times and washes his/her hands 1 minute. According to the difference in weight of the compress, it will be cataloged as follows: ≤ 1 gram -> continent. 1.1-9.9 grams -> mild incontinence. 10-49.9 grams -> moderate incontinence. > 50 grams -> severe incontinence
Patient satisfaction assessed by PGI-I (Patient Global Impression of Improvement)
PGI-I consider a patient satisfied when the patient answer " better or much better".
Patient satisfaction assessed by the "Global Satisfaction Test"
Global satisfaction assessment will be required, with a rank 1-5, being 1 very satisfied and 5 very dissatisfied.
Patient satisfaction assessed by the "Recommendations questionnarie"
The recommendation grade will be assessed through the question "will you recommend this surgical treatment for other patients?", the possible answer are Yes or No.
Evaluation of life quality improvement assessed by I-QoL questionnaire (Urinary Incontinence-Specific Quality of Life Instrument)
To assess the life quality impact, I-QoL questionnaire (Urinary Incontinence-Specific Quality of Life Instrument) will be used , this questionnaire, is composed by 22 items. The highest punctuation mean better life quality. The modification of 2.5 points, which has been considered in this questionnaire, is the minimum clinically significant modification in patients presenting SUI. This questionnaire is validated in Spanish.
Evaluation of sexual life, assessed by PSIQ 12 questionnaire (Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire )
To assess the impact on sexual life, the PSIQ 12 questionnaire (Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire ) will be used. It is composed of 12 items graded from "never" to "always". This questionnaire is validated in heterosexual women who have urinary incontinence and / or pelvic organ prolapse. Scores are calculated for each item with a value of "always = 0" and for "never = 4". It is used inversely in items 1-4.
Early complications assessed by Post-Mictional Residue
Are considered by the urgency of urination, the inability to void, the presence of PMR greater than 50% of the total volume after spontaneous voiding or the presence of pain that prevents ambulation, in the first 30 days after the intervention. For the elevated PMR assessment, perineal ultrasound measurement will be carried out after spontaneous micturition. If the PMR measurement will be higher or equal, probing would be performed to obtain the exact residue. If it is pathological, proceed according to the usual practice.
Early complications assessed by OAB-q questionnaire (Overactive Bladder symptom and health-related quality of life questionnaire)
OAB-q questionnaire (Overactive Bladder symptom and health-related quality of life questionnaire). Individual answer punctuation: lowest 0, highest 5 .If the score ≥8 will proceed according to the usual practice.
Long term complications assessed by OAB-q questionnaire (Overactive Bladder symptom and health-related quality of life questionnaire)
OAB-q questionnaire (Overactive Bladder symptom and health-related quality of life questionnaire). Individual answer punctuation: lowest 0, highest 5 .If the score ≥8 will proceed according to the usual practice.
Early complications assessed by VAS (Visual Analogue Scale)
Only when the patient has a pain that prevents ambulation. VAS: Pain scale for quantification of pain. Range 0 to 10. 0: No pain 5: Distressing pain 10: Unbearable pain
Long term complications assessed by "Extrusion" (integrity of the vaginal mucus)
Extrusion: The integrity of the vaginal mucus will be checked in all the visits that are made. If there is evidence of mesh extrusion, it is classified as asymptomatic / symptomatic and according to its size (greater or less than 1 cm).
Long term complications assessed by emergence of recurrent urinary tract infections (UTIs)
Urinary tract infection: in the presence of at least 1 monthly urinary tract infections (UTI), the patient will be considered to have developed repeat UTIs.
Long term complications assessed by "Emptying dysfunction"
Persistent urinary retention at 30 days will be considered as a long term complication.

Full Information

First Posted
April 8, 2019
Last Updated
September 27, 2023
Sponsor
Instituto de Investigacion Sanitaria La Fe
search

1. Study Identification

Unique Protocol Identification Number
NCT03916471
Brief Title
Comparison of Efficacy and Side Effects Between the Obtryx and Solyx Band With 5-year Follow-up.
Official Title
Comparison of Efficacy and Side Effects Between the Obtryx and Solyx Band With 5-year Follow-up. Prospective, Randomized and Non-inferiority Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 21, 2018 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Instituto de Investigacion Sanitaria La Fe

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Boston2018 post-market clinical study is a prospective, randomized, non-inferiority study to assess the efficacy and adverse events of the Solyx™ Single Incision Sling (SIS) System compared to the gold-standard Obtryx™ II Sling System, in patients with stress urinary incontinence (SUI) and long-term follow-up (5 years).
Detailed Description
Randomized prospective non-inferiority study, in which we evaluate patients with stress urinary incontinence (SUI) who undergo surgical treatment consisting of a minimal incision in the suburethral area of the vaginal mucosa for a mesh insertion in order to: Main Objective: To compare the continence rate (objective) between Solyx and Obtryx II meshes in patients with SUI. This rate will be determined by an effort test. Secondary Objectives: To compare the continence rate (subjective) between both meshes. To compare variations in Pad-Test. To asses patient satisfaction. To evaluate both techniques regarding quality and sexual life modifications. To compare both techniques regarding early complications (up to 30 days post implantation). To compare the appearance and persistence of late complications (from 30 days onwards).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stress Urinary Incontinence
Keywords
Stress Urinary Incontinence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
166 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
S (SOLYX)
Arm Type
Experimental
Arm Description
The Solyx™SIS System is an innovative mid-urethral sling single incision system consisting of a 9 cm long polypropylene mesh, whose mid-urethral portion (4 cm) is detanged to potentially resist deformation and to reduce irritation to the urethral wall. Snap-fit to delivery device tip allows for advanced placement control and, therefore, the tensioning through the forward and reverse functions performed with this delivery device.
Arm Title
O (OBTRYX II)
Arm Type
Experimental
Arm Description
The Obtryx II System (Halo) is a transobturator sling designed to allow inter-operative adjustability with minimal tissue disruption. It consists of two delivery devices (one patient right and one patient left) and one mesh assembly. The mesh assembly is comprised of a polypropylene knitted mesh with dilator legs and a center tab. At the distal ends of the dilator legs there are association loops designed to be placed in the needle slot of the distal end of the delivery device. The disposable delivery device consists of a handle with a stainless steel needle. The needle is designed to facilitate the passage of the mesh assembly through bodily tissues for placement through the obturator foramen.
Intervention Type
Device
Intervention Name(s)
Solyx™ SIS System
Intervention Description
Single-incision sling system
Intervention Type
Device
Intervention Name(s)
Obtryx™ II System (Halo)
Intervention Description
Transobturator Mid-urethral Sling System
Primary Outcome Measure Information:
Title
Continence rate (Objective) assessed by an effort test
Description
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Time Frame
Month 1
Title
Continence rate (Objective) assessed by an effort test
Description
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Time Frame
Month 6
Title
Continence rate (Objective) assessed by an effort test
Description
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Time Frame
Year 1
Title
Continence rate (Objective) assessed by an effort test
Description
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Time Frame
Year 2
Title
Continence rate (Objective) assessed by an effort test
Description
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Time Frame
Year 3
Title
Continence rate (Objective) assessed by an effort test
Description
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Time Frame
Year 4
Title
Continence rate (Objective) assessed by an effort test
Description
For the analysis of the objective cure of incontinence, an effort test will be carried out through three strokes of cough, with bladder volume between 200-300 ml in a lithotomy position.
Time Frame
Year 5
Secondary Outcome Measure Information:
Title
Continence rate (Subjective) assessed by Incontinence Questionnaire-Urinary Short Form (ICQ-SF)
Description
Incontinence Questionnaire-Urinary Short Form (ICQ-SF): continent patient when the reduction is equal to or greater than 50% of the value prior to the intervention.
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Pad test
Description
1 hour pad test: After a spontaneous urination the patient will place a compress that will be weighed previously. After, the patient has to drink a half liter of water in 15 minutes sitting. Between the minute 15 to 45 has to walk and / or go up / down stairs. From minute 45-60 the patient has to get up and sit 10 times, cough 10 times, run 1 minute, lift an object from the ground 10 times and washes his/her hands 1 minute. According to the difference in weight of the compress, it will be cataloged as follows: ≤ 1 gram -> continent. 1.1-9.9 grams -> mild incontinence. 10-49.9 grams -> moderate incontinence. > 50 grams -> severe incontinence
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Patient satisfaction assessed by PGI-I (Patient Global Impression of Improvement)
Description
PGI-I consider a patient satisfied when the patient answer " better or much better".
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Patient satisfaction assessed by the "Global Satisfaction Test"
Description
Global satisfaction assessment will be required, with a rank 1-5, being 1 very satisfied and 5 very dissatisfied.
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Patient satisfaction assessed by the "Recommendations questionnarie"
Description
The recommendation grade will be assessed through the question "will you recommend this surgical treatment for other patients?", the possible answer are Yes or No.
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Evaluation of life quality improvement assessed by I-QoL questionnaire (Urinary Incontinence-Specific Quality of Life Instrument)
Description
To assess the life quality impact, I-QoL questionnaire (Urinary Incontinence-Specific Quality of Life Instrument) will be used , this questionnaire, is composed by 22 items. The highest punctuation mean better life quality. The modification of 2.5 points, which has been considered in this questionnaire, is the minimum clinically significant modification in patients presenting SUI. This questionnaire is validated in Spanish.
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Evaluation of sexual life, assessed by PSIQ 12 questionnaire (Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire )
Description
To assess the impact on sexual life, the PSIQ 12 questionnaire (Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire ) will be used. It is composed of 12 items graded from "never" to "always". This questionnaire is validated in heterosexual women who have urinary incontinence and / or pelvic organ prolapse. Scores are calculated for each item with a value of "always = 0" and for "never = 4". It is used inversely in items 1-4.
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Early complications assessed by Post-Mictional Residue
Description
Are considered by the urgency of urination, the inability to void, the presence of PMR greater than 50% of the total volume after spontaneous voiding or the presence of pain that prevents ambulation, in the first 30 days after the intervention. For the elevated PMR assessment, perineal ultrasound measurement will be carried out after spontaneous micturition. If the PMR measurement will be higher or equal, probing would be performed to obtain the exact residue. If it is pathological, proceed according to the usual practice.
Time Frame
Day 0, 7-10 days after the intervention, Month 1
Title
Early complications assessed by OAB-q questionnaire (Overactive Bladder symptom and health-related quality of life questionnaire)
Description
OAB-q questionnaire (Overactive Bladder symptom and health-related quality of life questionnaire). Individual answer punctuation: lowest 0, highest 5 .If the score ≥8 will proceed according to the usual practice.
Time Frame
Day 0, 7-10 days after the intervention, Month 1
Title
Long term complications assessed by OAB-q questionnaire (Overactive Bladder symptom and health-related quality of life questionnaire)
Description
OAB-q questionnaire (Overactive Bladder symptom and health-related quality of life questionnaire). Individual answer punctuation: lowest 0, highest 5 .If the score ≥8 will proceed according to the usual practice.
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Early complications assessed by VAS (Visual Analogue Scale)
Description
Only when the patient has a pain that prevents ambulation. VAS: Pain scale for quantification of pain. Range 0 to 10. 0: No pain 5: Distressing pain 10: Unbearable pain
Time Frame
Day 0, 7-10 days after the intervention, Month 1
Title
Long term complications assessed by "Extrusion" (integrity of the vaginal mucus)
Description
Extrusion: The integrity of the vaginal mucus will be checked in all the visits that are made. If there is evidence of mesh extrusion, it is classified as asymptomatic / symptomatic and according to its size (greater or less than 1 cm).
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Long term complications assessed by emergence of recurrent urinary tract infections (UTIs)
Description
Urinary tract infection: in the presence of at least 1 monthly urinary tract infections (UTI), the patient will be considered to have developed repeat UTIs.
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.
Title
Long term complications assessed by "Emptying dysfunction"
Description
Persistent urinary retention at 30 days will be considered as a long term complication.
Time Frame
Month 1, month 6, year 1, year 2, year 3, year 4 and year 5.

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
female diagnosed with symtomatic stress urinary incontinence
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients diagnosed with symptomatic stress urinary incontinence candidates for stress-free bands Age > or = 40 years informed consent signed by the patient Exclusion Criteria: patients who are pregnant or wish to become patients who need anticoagulant active vaginal or urinary infection previous surgical interventions for the treatment of incontinence body mass index > 35
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maria Cortell
Phone
0034961246711
Email
investigacion_clinica@iislafe.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marta Garcia
Organizational Affiliation
Instituto de Investigación y Politécnico La Fe
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitario y Politécnico La Fe
City
Valencia
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Segura

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
15758785
Citation
Thom DH, Nygaard IE, Calhoun EA. Urologic diseases in America project: urinary incontinence in women-national trends in hospitalizations, office visits, treatment and economic impact. J Urol. 2005 Apr;173(4):1295-301. doi: 10.1097/01.ju.0000155679.77895.cb.
Results Reference
background
PubMed Identifier
19941278
Citation
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20. doi: 10.1002/nau.20798.
Results Reference
background
PubMed Identifier
12559262
Citation
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003 Jan;61(1):37-49. doi: 10.1016/s0090-4295(02)02243-4. No abstract available.
Results Reference
background
PubMed Identifier
12861145
Citation
Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003 Jul;189(1):98-101. doi: 10.1067/mob.2003.379.
Results Reference
background
PubMed Identifier
8798092
Citation
Ulmsten U, Henriksson L, Johnson P, Varhos G. An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 1996;7(2):81-5; discussion 85-6. doi: 10.1007/BF01902378.
Results Reference
background
PubMed Identifier
17970791
Citation
Ward KL, Hilton P; UK and Ireland TVT Trial Group. Tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence: 5-year follow up. BJOG. 2008 Jan;115(2):226-33. doi: 10.1111/j.1471-0528.2007.01548.x. Epub 2007 Oct 25.
Results Reference
background
PubMed Identifier
18535753
Citation
Nilsson CG, Palva K, Rezapour M, Falconer C. Eleven years prospective follow-up of the tension-free vaginal tape procedure for treatment of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Aug;19(8):1043-7. doi: 10.1007/s00192-008-0666-z. Epub 2008 Jun 6.
Results Reference
background
PubMed Identifier
28746980
Citation
Nambiar A, Cody JD, Jeffery ST, Aluko P. Single-incision sling operations for urinary incontinence in women. Cochrane Database Syst Rev. 2017 Jul 26;7(7):CD008709. doi: 10.1002/14651858.CD008709.pub3.
Results Reference
background
PubMed Identifier
26130017
Citation
Ford AA, Rogerson L, Cody JD, Ogah J. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2015 Jul 1;(7):CD006375. doi: 10.1002/14651858.CD006375.pub3.
Results Reference
background
PubMed Identifier
28756647
Citation
Ford AA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2017 Jul 31;7(7):CD006375. doi: 10.1002/14651858.CD006375.pub4.
Results Reference
background

Learn more about this trial

Comparison of Efficacy and Side Effects Between the Obtryx and Solyx Band With 5-year Follow-up.

We'll reach out to this number within 24 hrs